No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
267 |
4. Check minimum number of eventsNone |
267 |
5. Include endpointsNone |
267 |
6. Filter based on genotype QC (FinnGen only) |
241 |
Control definitions (FinnGen only)
- Control exclude
- H7_VITREOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF6
- Parent code in ICD-10
- H44
- Name in latin
- Endophthalmitis purulenta
Similar endpoints
↥List of similar endpoints to
Purulent endophthalmitis
based on the number of shared cases.
Similar with more cases:
- Disorders of globe
- Disorders of vitreous body and globe
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1886 | 976 | 889 |
| Only index persons | 1367 | 724 | 643 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 70.38 | 74.48 | 66.01 |
| Only index persons | 69.64 | 74.44 | 64.23 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 241 | 119 | 122 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.06 |
| Median age at first event (years) | 72.73 | 74.18 | 71.30 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 248
- Matched controls
- 2480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H44.0
ICD-10 Finland
Purulent endophthalmitis
+∞
291.8
219
*
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
48.8
219.1
160
89
CKA10
NOMESCO Finland
Biopsy of vitreous body
+∞
141.6
122
*
CKD65
NOMESCO Finland
Pars plana or pars plicata vitrectomy
52.7
128.5
77
21
WX140
NOMESCO Finland
Parabulbar anesthesy
26.0
128.3
104
67
CKD91
NOMESCO Finland
Extended vitrectomy through pars plana
41.2
75.3
47
14
H44.1
ICD-10 Finland
Other endophthalmitis
+∞
61.0
56
*
H35.31
ICD-10 Finland
Senile macular degeneration (atrophic)(exudative)
11.5
59.9
73
87
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
8.5
56.4
95
168
H33.0
ICD-10 Finland
Retinal detachment with retinal break
17.0
49.7
44
31
Z96.1
ICD-10 Finland
Presence of intraocular lens
6.4
47.2
122
325
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
13.5
42.5
43
38
XCW99
NOMESCO Finland
Other investigative procedure of eye
6.9
40.3
78
155
S01ED51
ATC
timolol, combinations; ophthalmic
6.9
37.9
71
136
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
5.1
32.8
172
767
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
7.6
32.3
52
84
H43.1
ICD-10 Finland
Vitreous haemorrhage
+∞
30.9
29
*
TCH12
NOMESCO Finland
Sample aspiration from anterior chambre
+∞
28.7
27
*
S01ED01
ATC
timolol; ophthalmic
8.3
28.0
40
56
WX100
NOMESCO Finland
Conjunctival surface anesthesia
4.6
27.1
88
267
CHB10
NOMESCO Finland
Puncture of anterior chamber of eye with irrigation
50.3
26.2
31
7
H35.38
ICD-10 Finland
Preretinal fibrosis of the macula
7.1
24.5
40
65
S01EC01
ATC
acetazolamide; systemic
10.1
23.4
28
31
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
3.9
22.8
168
873
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.0
22.3
86
291
H16.0
ICD-10 Finland
Corneal ulcer
7.8
22.2
33
48
3600A
ICD-9 Finland
Disorders of the globe, Purulent endophthalmitis
+∞
20.1
19
*
S01EA05
ATC
brimonidine; ophthalmic
9.2
19.6
25
30
WX142
NOMESCO Finland
Sub-tenon anesthesy
50.5
19.6
23
5
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
3.4
19.0
161
875
114
Kela drug reimbursment
Glaucoma
4.2
19.0
62
184
CKD92
NOMESCO Finland
Combined vitrectomy and retinal procedure
21.2
17.3
25
13
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
22.0
16.8
24
12
H25.1
ICD-10 Finland
Senile nuclear cataract
3.1
16.7
143
764
H26.4
ICD-10 Finland
After-cataract
3.7
16.6
63
207
XCK10
NOMESCO Finland
Photography of fundus of eye
3.9
16.4
58
181
S01EE01
ATC
latanoprost; ophthalmic
4.4
15.9
45
119
CKC12
NOMESCO Finland
Photocoagulation of retina
6.8
15.8
26
42
CKW99
NOMESCO Finland
Other operation on choroid, vitreous body and retina
40.9
15.6
19
5
H35.39
ICD-10 Finland
Degeneration of macula and posterior pole
6.7
14.5
24
39
S01EA03
ATC
apraclonidine; ophthalmic
24.0
14.5
20
9
H20.9
ICD-10 Finland
Iridocyclitis, unspecified
25.6
14.0
19
8
XCK00
NOMESCO Finland
Perimetry
4.4
13.5
37
95
S01EC04
ATC
brinzolamide; ophthalmic
5.0
13.5
31
69
CJB10
NOMESCO Finland
Laser discission of secondary cataract
3.5
13.2
52
173
H20.1
ICD-10 Finland
Chronic iridocyclitis
52.9
13.0
15
*
H43.8
ICD-10 Finland
Other disorders of vitreous body
14.2
12.7
21
16
H02AB06
ATC
prednisolone; systemic
2.7
12.7
151
913
CKD93
NOMESCO Finland
Extended combined procedure on vitreous body and retina
136.6
12.6
13
*
H26.2
ICD-10 Finland
Complicated cataract
28.3
12.2
16
6
WX002
NOMESCO Finland
Sedation and analgesia
2.9
12.1
76
332
XCH00
NOMESCO Finland
Eye pressure measurement
4.8
12.1
29
67
S01EE05
ATC
tafluprost; ophthalmic
5.2
12.0
26
55
WX006
NOMESCO Finland
Intravenous sedation or analgesia without general anesthesia
4.2
11.3
32
84
ZX198
NOMESCO Finland
Other local administration
21.3
11.3
16
8
WX704
NOMESCO Finland
Intubation
4.5
11.2
29
71
CA1AE
NOMESCO Finland
Eye and orbita ultrasound examination
62.8
10.7
12
*
H33.5
ICD-10 Finland
Other retinal detachments
62.8
10.7
12
*
CKD70
NOMESCO Finland
Excision of preretinal or epiretinal membrane
11.3
10.5
19
18
S01EC54
ATC
brinzolamide, combinations; ophthalmic
11.3
10.5
19
18
ZXA00
NOMESCO Finland
Right side
2.5
10.4
96
503
H16.9
ICD-10 Finland
Keratitis, unspecified
15.4
10.1
16
11
CKD40
NOMESCO Finland
Endophotocoagulation of retina
12.9
10.0
17
14
H40.0
ICD-10 Finland
Glaucoma suspect
3.5
9.8
37
119
XCD10
NOMESCO Finland
Electrophysiological examination of eye
5.6
9.8
19
36
CKD94
NOMESCO Finland
Combined vitrectomy and procedure on lens through pars plana
10.7
9.7
18
18
S01BC03
ATC
diclofenac; ophthalmic
10.7
9.7
18
18
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
5.5
9.5
19
37
H35.36
ICD-10 Finland
Macular cyst
31.4
9.5
12
*
3643
FHL
Vitrectomy through pars Plana
38.2
9.1
11
*
ZXD05
NOMESCO Finland
Urgent procedure
2.3
9.0
92
499
ZXA10
NOMESCO Finland
Bilateral
2.5
8.8
72
353
S01BA01
ATC
dexamethasone; ophthalmic
4.9
8.8
20
44
CHC05
NOMESCO Finland
Iridotomy
9.5
8.7
17
19
H35.30
ICD-10 Finland
Kuhnt-Junius degeneration
3.2
8.5
37
130
CHD50
NOMESCO Finland
Shunt operation on anterior chamber
93.1
8.5
9
*
TCK20
NOMESCO Finland
Needle biopsy of vitreous body
+∞
8.4
8
*
CM2X4
NOMESCO Finland
Follow-up OCT of age-related macular degeneration lesions
15.2
8.3
13
9
CM2S4
NOMESCO Finland
Follow-up photography of age-related macular degeneration lesions
22.9
8.1
11
5
S01AX11
ATC
[U] ofloxacin
4.7
8.0
19
43
H57.1
ICD-10 Finland
Ocular pain
4.9
8.0
18
39
H34.8
ICD-10 Finland
Other retinal vascular occlusions
6.8
7.9
19
30
S01BA04
ATC
prednisolone; ophthalmic
7.1
7.7
18
27
A10AA02, ,
ATC
4.4
7.7
20
49
Z94.7
ICD-10 Finland
Corneal transplant status
25.9
7.6
10
*
ZXA05
NOMESCO Finland
Left side
2.2
7.3
79
432
36600
ICD-8 Finland
Other inflammation of uveal tract, Abscessus oculi. Uveitis suppurativa. Panophthalmitis
+∞
7.3
7
*
CK9F4
NOMESCO Finland
Fluorescein angiography (FAG) of choroid and retina
16.4
7.3
11
7
TPH07
NOMESCO Finland
Cathetrisation of artery
2.7
7.2
42
173
H40.9
ICD-10 Finland
Glaucoma, unspecified
6.4
7.2
18
30
CKD15
NOMESCO Finland
Injection of vitreous substitute
31.0
7.2
9
*
CHD65
NOMESCO Finland
Nonpenetrating glaucoma surgery
20.7
7.2
10
5
CKD10
NOMESCO Finland
Insufflation of vitreous cavity
7.9
7.0
15
20
TPH04
NOMESCO Finland
Cathetrisation of vein
2.2
6.9
69
365
H3603, E103,
ICD-10 Finland
41.2
6.8
8
*
H20.8
ICD-10 Finland
Other iridocyclitis
41.2
6.8
8
*
XCD20
NOMESCO Finland
Photoangiography of eye
7.2
6.6
15
22
TCG00
NOMESCO Finland
Protection of cornea and sclera with soft lens
71.6
6.5
7
*
CHF05
NOMESCO Finland
Transscleral laser coagulation of ciliary body
14.8
6.4
10
7
H40.11
ICD-10 Finland
Low pressure glaucoma
5.8
6.4
17
31
127
Kela drug reimbursment
Transplant complication
18.6
6.3
9
5
S01EE03
ATC
bimatoprost; ophthalmic
5.6
6.3
17
32
H44.5
ICD-10 Finland
Degenerated conditions of globe
+∞
6.3
6
*
3626
FHL
Extracapsular cataract surgery and implantation of an artificial lens
6.6
6.3
15
24
H19.1*B00.5
ICD-10 Finland
Herpesviral keratoconjunctivitis
13.0
6.1
10
8
Z3229
NOMESCO Finland
Other healthcare associate professional
2.7
6.1
34
137
J01MA12
ATC
levofloxacin; systemic
2.2
6.1
62
329
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
81
67
17.47
85.77
1.8
1.5
—
—
—
0
0
72
52
19.10
81.90
2.0
1.4
—
—
—
0
0
19
18
11.33
10.47
1.5
1.2
—
—
—
0
0
61
287
2.49
8.08
5.9
6.4
1.20
1.15
mmol/l
0.02
45
237
13
14
9.73
6.87
1.5
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
74
3.01
4.79
3.4
2.3
0.27
0.40
iu/ml
1.07
14
41
146
1106
1.78
4.64
5.3
4.4
0.00
0.00
estimate
-0.00
34
251
147
1117
1.78
4.61
5.5
4.4
0.00
6.22
estimate
0.50
35
261
8
8
10.28
4.55
1.1
1.3
585.38
1116.75
u/ml
—
8
8
155
1200
1.78
4.52
9.9
9.4
4.39
4.29
e9/l
0.18
134
1039
108
758
1.75
4.42
4.7
4.1
25.53
8.82
mg/mmol
0.93
74
484
147
1129
1.74
4.33
5.6
4.5
0.00
1.27
estimate
0.51
31
239
152
1183
1.74
4.23
12.2
7.0
1.19
1.21
mmol/l
2.20
130
1023
9
13
7.14
4.20
1.1
1.2
—
—
—
0
0
47
259
2.01
4.09
9.0
3.7
1.34
2.02
mmol/l
0.58
39
214
51
291
1.95
4.02
2.9
4.5
258.37
250.42
u/l
0.18
46
275
8
11
7.47
3.89
1.0
1.0
—
—
—
0
0
53
312
1.89
3.80
1.6
1.8
—
—
—
0
0
138
1068
1.66
3.73
9.8
6.1
1.19
1.21
mmol/l
2.84
128
977
51
300
1.88
3.66
1.6
1.9
—
—
—
0
0
72
472
1.74
3.62
5.4
4.7
1.02
1.02
kg/l
0.19
56
315
95
672
1.67
3.61
4.1
2.5
53.58
63.88
u/l
0.76
90
626
34
175
2.09
3.55
1.6
1.7
—
—
—
0
0
90
640
1.64
3.30
5.1
4.6
0.00
0.01
estimate
0.50
30
230
6
7
8.74
3.28
1.2
1.0
2470.17
1396.57
miu/ml
—
6
7
5
5
10.17
2.99
1.0
1.0
—
—
—
0
0
119
926
1.55
2.89
3.7
3.0
—
—
estimate
—
0
0
57
372
1.69
2.86
4.9
3.4
1.21
2.25
e6/l
1.04
29
189
61
410
1.65
2.74
4.7
3.2
1.31
1.11
e6/l
0.17
33
225
130
1041
1.52
2.71
7.1
4.5
33.92
34.91
g/l
1.14
120
967
8
19
4.31
2.70
2.1
2.5
—
—
—
0
0
62
420
1.63
2.70
1.8
1.9
—
—
—
0
0
177
1518
1.58
2.68
5.2
4.5
18.07
14.16
mm/h
1.57
162
1390
89
662
1.54
2.59
5.1
3.5
0.45
0.41
e6/l
0.06
65
502
12
45
2.75
2.49
3.8
2.6
11.84
10.27
pmol/l
0.17
12
45
38
230
1.77
2.48
8.4
3.0
4.45
4.17
kpa
0.38
38
223
108
845
1.49
2.45
5.2
4.5
0.00
0.03
estimate
1.05
26
208
19
91
2.18
2.40
2.9
3.2
—
—
—
0
0
184
1613
1.55
2.33
10.1
7.9
82.03
81.51
u/l
0.05
177
1510
172
1488
1.51
2.30
5.5
4.3
15.14
15.14
pmol/l
0.01
150
1312
177
1551
1.49
2.14
37.9
24.0
13.85
13.90
%
0.17
177
1537
198
1786
1.54
1.98
6.9
5.5
2.21
2.02
mu/l
1.02
180
1598
88
685
1.44
1.96
4.0
3.0
35.66
33.00
u/l
0.15
83
640
11
46
2.46
1.88
1.8
2.9
25.55
34.23
umol/l
1.42
11
39
80
625
1.41
1.72
2.6
2.3
2.79
3.15
mg/l
0.55
74
538
34
223
1.61
1.68
3.5
3.1
66.33
66.32
g/l
0.00
27
202
169
1499
1.40
1.67
37.8
25.2
332.49
331.24
g/l
1.02
169
1493
38
257
1.57
1.66
4.1
3.6
—
—
—
0
0
8
32
2.55
1.61
1.1
1.1
—
—
—
0
0
208
1925
1.50
1.55
29.1
18.6
29.51
25.14
mg/l
1.01
187
1634
207
1914
1.49
1.55
7.3
6.3
2.35
2.54
mmol/l
2.45
190
1732
31
204
1.59
1.52
4.0
2.4
31.12
34.46
u/l
0.34
26
169
202
1861
1.46
1.52
6.4
5.7
6.59
6.11
mmol/l
1.86
184
1667
17
94
1.87
1.51
3.9
1.8
1054.00
326.53
ug/l
0.67
17
89
214
1996
1.53
1.49
36.1
22.8
139.29
139.54
mmol/l
0.63
214
1948
214
1996
1.53
1.49
36.6
23.0
4.03
4.00
mmol/l
0.85
214
1946
72
566
1.38
1.47
3.2
3.0
377.67
358.62
umol/l
0.56
60
485
5
16
3.17
1.44
1.2
1.4
—
—
—
0
0
89
727
1.35
1.43
2.6
2.1
193.32
211.40
u/l
0.16
84
689
114
967
1.33
1.42
2.5
2.6
—
—
—
0
0
23
143
1.67
1.41
2.9
3.0
0.67
1.73
mmol/l
0.39
14
101
7
29
2.45
1.40
1.0
1.5
—
—
—
0
0
202
1871
1.43
1.38
6.3
5.4
4.25
4.45
mmol/l
1.90
184
1697
6
23
2.65
1.37
1.0
1.5
—
—
—
0
0
112
952
1.32
1.36
2.9
2.5
74.79
78.95
nmol/l
0.82
99
829
31
210
1.54
1.36
2.6
2.5
8.98
5.15
ug/l
0.76
24
182
95
792
1.32
1.31
2.0
2.0
1.28
1.29
mmol/l
0.04
80
645
11
56
2.01
1.24
1.2
1.5
—
—
—
0
0
10
49
2.08
1.23
1.2
1.5
—
—
—
0
0
75
609
1.33
1.23
5.4
3.9
0.00
0.12
estimate
0.50
23
205
28
190
1.53
1.23
8.6
4.1
1.21
1.22
mmol/l
0.24
19
164
200
1861
1.39
1.22
6.2
5.3
1.43
1.45
mmol/l
0.33
181
1681
10
184
0.52
1.19
1.5
1.4
—
—
—
0
0
22
144
1.58
1.13
1.7
1.8
—
—
—
0
0
13
73
1.82
1.13
5.2
2.0
1.69
1.71
mg/l
0.03
13
60
35
254
1.44
1.12
8.4
9.2
—
—
—
0
0
7
31
2.29
1.11
1.0
1.1
—
—
—
0
0
8
41
1.98
1.10
1.4
1.4
—
—
—
0
0
8
41
1.98
1.10
1.4
1.4
—
—
—
0
0
8
41
1.98
1.10
1.3
1.5
—
—
—
0
0
18
273
0.63
1.06
6.6
5.0
34.30
33.34
%
—
10
167
198
1853
1.34
1.05
9.7
7.2
43.43
40.45
mmol/mol
2.76
185
1707
11
60
1.87
1.04
2.5
2.3
370.07
85.65
ug/min
—
6
35
61
493
1.31
1.03
4.2
2.6
—
—
—
0
0
212
2008
1.38
1.01
16.0
12.7
26.63
24.24
u/l
0.39
205
1937
9
49
1.87
0.99
2.7
1.3
—
—
—
0
0
5
23
2.20
0.98
1.2
1.7
—
—
—
0
0
190
1777
1.30
0.95
5.3
4.5
1.30
1.26
mmol/l
0.34
170
1586
196
1842
1.31
0.93
28.8
18.9
68.84
73.36
ml/min/173m2
2.17
185
1722
8
42
1.93
0.89
1.6
2.1
—
—
—
0
0
6
31
1.96
0.85
1.0
1.4
—
—
—
0
0
57
469
1.28
0.85
1.9
1.7
1.25
1.63
mg/l
0.72
43
380
213
2033
1.34
0.83
37.6
25.2
95.90
83.40
umol/l
1.84
213
2003
23
164
1.44
0.83
2.3
3.1
38.00
57.65
ml/min/173m2
—
7
75
8
46
1.76
0.83
1.3
1.6
—
—
—
0
0
214
2046
1.34
0.81
42.8
28.5
92.20
91.65
fl
1.14
214
2016
214
2047
1.33
0.80
43.0
28.6
242.23
239.27
e9/l
0.25
214
2004
214
2047
1.33
0.80
43.4
28.8
130.94
132.72
g/l
0.84
214
2017
214
2047
1.33
0.80
43.6
29.0
38.93
39.72
%
1.04
214
2017
26
192
1.40
0.79
8.9
3.7
142.34
88.61
ng/l
0.84
20
162
90
788
1.22
0.78
3.1
3.1
2.31
2.35
mmol/l
2.19
81
699
115
1035
1.21
0.75
2.5
2.2
100.08
95.72
pmol/l
0.43
62
530
101
898
1.21
0.74
4.5
3.1
148.40
142.41
ug/l
0.13
93
816
83
727
1.21
0.71
2.0
1.8
20.82
20.77
nmol/l
0.01
75
597
59
500
1.24
0.69
2.4
2.9
2.43
2.46
mmol/l
1.33
54
446
132
1211
1.19
0.68
3.8
3.3
43.54
51.77
u/l
1.00
124
1118
5
28
1.80
0.66
1.0
1.8
—
—
—
0
0
104
936
1.19
0.66
6.0
4.5
64.38
43.37
ng/l
0.74
80
748
14
96
1.49
0.63
2.4
2.8
10.67
2508.35
u/ml
—
9
84
10
63
1.61
0.62
1.7
1.2
—
—
—
0
0
31
249
1.28
0.57
4.8
4.0
3.57
54.54
ug/l
0.94
21
204
5
90
0.55
0.56
1.0
1.0
—
—
—
0
0
13
91
1.45
0.54
2.6
3.7
1.14
3.66
ratio
—
5
47
10
66
1.54
0.53
1.0
1.6
—
—
—
0
0
6
40
1.51
0.52
1.5
1.4
295.00
189.41
pmol/l
—
6
40
9
65
1.40
0.51
1.0
1.6
—
—
—
0
0
9
65
1.40
0.51
1.0
1.5
—
—
—
0
0
18
136
1.35
0.51
1.3
1.4
—
—
—
0
0
7
46
1.54
0.48
1.4
1.8
13.43
2.04
mg/l
—
7
36
68
611
1.16
0.43
5.2
4.8
23.60
22.39
%
0.31
39
315
8
61
1.32
0.40
1.0
1.2
—
—
—
0
0
8
61
1.32
0.40
1.0
1.2
—
—
—
0
0
6
41
1.47
0.36
1.0
1.7
—
—
—
0
0
5
80
0.62
0.36
2.8
2.1
—
—
—
0
0
18
221
0.80
0.35
1.7
1.5
—
—
—
0
0
6
46
1.31
0.33
1.2
1.3
—
—
—
0
0
6
47
1.28
0.32
1.3
1.2
21.66
23.66
u/l
—
6
40
91
852
1.11
0.30
3.7
3.4
3020.70
1698.51
ng/l
0.90
81
725
83
777
1.10
0.27
5.7
5.8
3.69
2.61
ug/l
0.51
72
696
8
66
1.22
0.27
1.3
1.5
—
—
—
0
0
5
75
0.66
0.26
2.8
1.9
—
—
—
0
0
5
39
1.29
0.23
5.4
2.6
1.15
1.20
mmol/l
—
5
39
5
40
1.26
0.22
5.4
2.5
106.00
105.75
mmol/l
—
5
40
38
345
1.12
0.22
1.3
1.3
59.99
36.78
iu/ml
0.41
14
125
0
11
0.00
0.21
0.0
3.5
—
205.64
—
0
11
0
11
0.00
0.21
0.0
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.4
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
7.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
11
90
1.23
0.19
1.4
1.3
—
—
—
0
0
10
82
1.23
0.17
1.1
1.3
—
—
—
0
0
7
63
1.11
0.17
1.0
1.4
—
—
—
0
0
9
79
1.14
0.15
2.4
2.1
0.00
0.00
g/l
—
9
72
28
306
0.90
0.15
1.6
1.3
1.41
11.61
u/ml
—
8
111
10
117
0.85
0.13
1.2
1.2
101.45
276.18
u/ml
—
10
106
5
44
1.14
0.10
1.2
1.5
—
—
—
0
0
43
449
0.95
0.08
1.3
1.3
0.86
1.78
u/ml
—
10
117
22
205
1.08
0.08
1.2
1.3
—
—
—
0
0
9
87
1.04
0.07
1.8
2.0
—
—
—
0
0
10
92
1.09
0.03
1.4
2.2
—
—
—
0
0
46
469
0.98
0.02
2.0
1.8
1397.00
1206.43
nmol/l
0.43
35
347
52
529
0.98
0.02
2.0
1.9
420.18
442.48
pmol/l
0.29
40
432
46
467
0.98
0.01
3.4
3.3
0.99
0.78
ug/l
0.50
33
307
5
54
0.92
-0.00
1.0
1.2
—
20.52
—
0
5
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.6
—
13.81
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_PURENDOPHTHALMITIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_PURENDOPHTHALMITIS | 1.168 [0.94, 1.45] | 0.163 |
| Birth year | 0.996 [0.99, 1.0] | 0.398 |
During the follow-up period (1.1.1998 — 31.12.2019), 234 out of 595 females with H7_PURENDOPHTHALMITIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_PURENDOPHTHALMITIS | 1.545 [1.18, 2.02] | 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 168 out of 486 males with H7_PURENDOPHTHALMITIS died.
Mortality risk
Mortality risk for people of age
years, who have H7_PURENDOPHTHALMITIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.127% | 0.329% |
| 5 | 0.731% | 1.799% |
| 10 | 1.797% | 4.371% |
| 15 | 3.428% | 8.472% |
| 20 | 5.99% | 13.724% |
Relationships between endpoints
↥Index endpoint: H7_PURENDOPHTHALMITIS – Purulent endophthalmitis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data